Last reviewed · How we verify
Bykahepar (CLANOBUTIN)
Bykahepar (generic name: CLANOBUTIN) is a drug. It is currently in Phase 2 development.
Bykahepar works by binding to and altering the activity of specific proteins or enzymes in the body.
Bykahepar, also known as Clanobutin, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. The approved indications for Bykahepar are also unknown. As a small molecule, it is likely to work by interacting with specific biological molecules to produce a therapeutic effect. Further research is needed to fully understand its mechanism of action and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CLANOBUTIN |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a factory with many different machines working together. Bykahepar is like a tool that fits into one of these machines, changing how it works to produce a desired effect. This can help to slow down or speed up certain processes in the body, depending on the specific goal of the treatment.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bykahepar CI brief — competitive landscape report
- Bykahepar updates RSS · CI watch RSS
Frequently asked questions about Bykahepar
What is Bykahepar?
How does Bykahepar work?
What is the generic name of Bykahepar?
What development phase is Bykahepar in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing